North America Breast Cancer Screening Tests Market Size (2024 - 2029)

North America Breast Cancer Screening Tests Market Analysis

The North America Breast Cancer Screening Tests Market size is expected to grow from USD 1.16 billion in 2023 to USD 1.74 billion by 2028, at a CAGR of 8.44% during the forecast period (2023-2028).

• The COVID-19 pandemic significantly impacted the breast cancer screening test market. Diagnostic procedures were postponed at the pandemic's beginning as the hospitals and surgeons were advised to postpone or cancel elective courses. For instance, according to a study published by the National Library of Medicine (NLM) in June 2022, mammography rates were more impacted during the pandemic than the number of breast cancer operations. By 2030, the study projects 950 cumulative excess breast cancer deaths related to reduced screening and 1,314 associated with delayed diagnosis of symptomatic cases.
• The study also stated that the initial pandemic-related disruptions in breast cancer care would have a negligible long-term effect on breast cancer mortality. This has impacted the growth of the breast cancer screening test market during the pandemic. However, the market is gradually stabilizing as COVID-19 cases are declining, resulting in the return of the normal demand levels for diagnostic procedures.
• The primary factors driving the market growth include the rising incidence of breast cancer and technological advancements in breast cancer screening. For instance, according to the Canadian Cancer Society update, in May 2022, 28,600 Canadian women were diagnosed with breast cancer, representing 25% of all new cancer cases in women in 2022.
• Furthermore, according to a Center for Disease Prevention (CDC) update in September 2022, the risk of breast cancer increases with age. Most breast cancers are diagnosed after age 50. Thus, with an increase in breast cancer cases due to the rise in the geriatric population, the demand for breast cancer screening tests increases, thereby driving the market's growth.
• Furthermore, technological advances in imaging are creating new opportunities for improvements in screening and early detection. For instance, according to National Cancer Institute (NCI), in January 2022, NCI funded a large-scale randomized breast screening trial, the tomosynthesis mammographic imaging screening trial (TMIST), to compare the number of advanced cancers detected in women screened for five years with 3-D mammography with the number seen in women screened with 2-D mammography. Such initiatives are expected to increase the demand for breast cancer screening tests, eventually driving the market's growth.
• Additionally, the rising initiative of critical players in developing innovative strategies is further expected to drive market growth over the forecast period. For instance, in October 2022, the American College of Radiology (ACR) launched the contrast-enhanced mammography imaging screening Trial (CMIST) in collaboration with the Breast Cancer Research Foundation (BCRF) and GE Healthcare. The trial determined whether contrast-enhanced mammography improves breast cancer detection and reduces false-positive exams in women with dense breasts. Such initiatives will lead to increased adoption of breast cancer screening, driving market growth.
• Therefore, the factors mentioned above, such as the rising incidence of breast cancer and technological advancements in breast cancer screening, are attributed collectively to the studied market growth over the forecast period. However, controversies related to mammography and side effects of radiation during screening tests and errors in screening are the major factors restraining the market's growth.

North America Breast Cancer Screening Tests Industry Segmentation

As per the scope of the report, breast cancer screening is carried out to detect cancer in its early stages and ensure timely treatment for the patients.

The North American breast cancer screening tests market is segmented by test (genomic tests and imaging tests (mammogram, ultrasound, MRI, tomography, and other imaging tests)) and geography (United States, Canada, and Mexico).

The report offers the value (in USD) for the above segments.